LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

Strona główna・Stock List・Gossamer Bio Inc

Gossamer Bio Inc

Open

SectorHealthcare

3.27 -3.82

Buy Sell

Overview

Share price change

24h

Current

Min

3.2800000000000002

Max

3.42

Key metrics
By Trading Economics
Income	-9.9M -48M
Sales	1.8M 13M
EPS	-0.21
Profit margin	-362.728
Employees	144
EBITDA	-10M -45M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+215.79% upside

Market Stats
By TradingEconomics
Market Cap	180M 727M
Previous open	7.09
Previous close	3.27

News Sentiment

By Acuity

50%

178 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

1.06 / 1.23 Support & Resistance

Gossamer Bio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 gru 2025, 20:41 UTC

Earnings

Major Market Movers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 gru 2025, 18:14 UTC

Acquisitions, Mergers, Takeovers

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 gru 2025, 17:43 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 gru 2025, 17:01 UTC

Earnings

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 gru 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 gru 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4 gru 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4 gru 2025, 21:37 UTC

Earnings

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 gru 2025, 21:36 UTC

Earnings

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 gru 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 gru 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 gru 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 gru 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 gru 2025, 19:44 UTC

Acquisitions, Mergers, Takeovers

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 gru 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 gru 2025, 19:01 UTC

Acquisitions, Mergers, Takeovers

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 gru 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 gru 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 gru 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 gru 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 gru 2025, 16:33 UTC

Market Talk

Earnings

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Comparison

Price change

Gossamer Bio Inc Forecast

Price Target

By TipRanks

215.79% upside

12 Months Forecast

Average 10.8 USD 215.79%

High 15 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forGossamer Bio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Gossamer Bio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.06 / 1.23Support & Resistance

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

178 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.